Bradley K Ackerson
Overview
Explore the profile of Bradley K Ackerson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
2124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ku J, Tartof S, Contreras R, Ackerson B, Chen L, Reyes I, et al.
J Infect Dis
. 2024 May;
230(6):e1344-e1354.
PMID: 38743691
Background: Data on antibiotic resistance of uropathogens for urinary tract infection (UTI) recurrences are lacking. Methods: In a retrospective cohort of adults at Kaiser Permanente Southern California with culture-confirmed index...
12.
Lewnard J, Mahale P, Malden D, Hong V, Ackerson B, Lewin B, et al.
medRxiv
. 2024 May;
PMID: 38699313
The SARS-CoV-2 BA.2.86 lineage, and its sublineage JN.1 in particular, achieved widespread transmission in the US during winter 2023-24. However, the increase in infections was not accompanied by increases in...
13.
Ackerson B, Bruxvoort K, Qian L, Sy L, Qiu S, Tubert J, et al.
Hum Vaccin Immunother
. 2024 Apr;
20(1):2335052.
PMID: 38575149
Emerging SARS-CoV-2 sublineages continue to cause serious COVID-19 disease, but most individuals have not received any COVID-19 vaccine for >1 year. Assessment of long-term effectiveness of bivalent COVID-19 vaccines against...
14.
Malden D, McLaughlin J, Hong V, Lewnard J, Ackerson B, Puzniak L, et al.
Sci Rep
. 2024 Mar;
14(1):7485.
PMID: 38553527
A clear understanding of real-world uptake of nirmatrelvir-ritonavir for treatment of SARS-CoV-2 can inform treatment allocation strategies and improve interpretation of effectiveness studies. We used data from a large US...
15.
Tartof S, Slezak J, Puzniak L, Hong V, Frankland T, Ackerson B, et al.
Lancet Respir Med
. 2023 Oct;
11(12):1089-1100.
PMID: 37898148
Background: XBB-related omicron sublineages have recently replaced BA.4/5 as the predominant omicron sublineages in the USA and other regions globally. Despite preliminary signs of immune evasion of XBB sublineages, few...
16.
Tseng H, Ackerson B, Sy L, Tubert J, Luo Y, Qiu S, et al.
Nat Commun
. 2023 Sep;
14(1):5851.
PMID: 37730701
The bivalent (original and Omicron BA.4/BA.5) mRNA-1273 COVID-19 vaccine was authorized to offer broader protection against COVID-19. We conducted a matched cohort study to evaluate the effectiveness of the bivalent...
17.
Tartof S, Frankland T, Slezak J, Puzniak L, Ackerson B, Jodar L, et al.
JAMA
. 2023 Sep;
330(13):1282-1284.
PMID: 37712905
No abstract available.
18.
Skarbinski J, Fischer H, Hong V, Liu L, Yau V, Incerti D, et al.
Clin Pharmacol Ther
. 2023 Aug;
114(5):1073-1081.
PMID: 37571812
Randomized controlled trials (RCTs) remain the gold standard for evaluating treatment efficacy, but real-world evidence can supplement RCT results. Tocilizumab was not found to reduce 28-day mortality in a phase...
19.
Ku J, Sy L, Qian L, Ackerson B, Luo Y, Tubert J, et al.
Vaccine
. 2023 Jun;
41(29):4212-4219.
PMID: 37301708
We evaluated relative vaccine effectiveness (rVE) of 4- vs. 3-dose mRNA-1273 against SARS-CoV-2 infection, and COVID-19 hospitalization and death in immunocompetent adults aged ≥50 years at Kaiser Permanente Southern California....
20.
Ku J, Sy L, Qian L, Ackerson B, Luo Y, Tubert J, et al.
Vaccine
. 2023 May;
41(24):3636-3646.
PMID: 37173268
Background: Data on the effectiveness of the 3-dose mRNA-1273 primary series are limited, particularly in comparison to 2 doses. Given suboptimal COVID-19 vaccine uptake among immunocompromised populations, it is important...